The Effect of Escitalopram on the Pharmacokinetics and Pharmacodynamics of Tramadol in Healthy Subjects

• Status: Completed
• Trial end date: 2008-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Escitalopram will be given to a panel of 16 healthy subject for 9 days. On the ninth day a single dose of tramadol is administered to the subjects and pharmacokinetic(PK) and pharmacodynamic(PD) measurements are done for the next 24 hours.

It is stated that escitalopram is only a weak inhibitor of CYP2D6 and therefore no effect is seen in Pk or PK of tramadol

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Southern Denmark
• Collaborator: H. Lundbeck A/S
• Treatments: Citalopram; Dexetimide; Tramadol

Criteria

Inclusion Criteria:

• Healthy

• Age: 18 - 45 years

• CYP2D6 phenotyped as extensive metabolizer

• CYP2C19 phenotyped as extensive metabolizer

Exclusion Criteria:

• Alcohol or drug abuse